Health Canada approves Acadia’s DAYBUE for Rett syndrome
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome in adult and paediatric patients aged two years and above. Rett syndrome is a rare neurodevelopmental disorder that predominantly …